......DE..ESFRGB..IT............................................................
*
J
DIM350 (Ver 2.1 Jan 2001) 2999001/0
20040419
1054669
CORRECTED EUROPEAN PATENT SPECIFICATION
B9
B1
20040915
W1
DE
Beschreibung
EN
Description
FR
Description
EP
99910217.1
19990211
20000918
20020221
en
en
en
98102675
19980217
EP
20040915
200438
20001129
200048
20030716
200329
20030129
20040915
200438
7
7A 61K 31/435 A
7A 61P 15/10 B
7A 61P 25/00 B
de
VERWENDUNG VON THIADIAZOLO[4,3-A]PYRIDINE DERIVATEN
en
USE OF THIADIAZOLO[4,3-A]PYRIDINE DERIVATIVES
fr
EMPLOI DE DERIVES DE THIADIAZOLO-PYRIDINE
WO-A-93/06109
JP-A- 60 246 389
BERKOW R. (ED.): "MERCK MANUAL OF DIAGNOSIS AND THERAPY." 1992 , MERCK RESEARCH LABORATORIES , RAHWAY N.J. XP002081579 215310 page 343, paragraphs 5-7
POTTS ET AL.: "Synthesis of ring-fused 1,2,4-thiadiazoles" SYNTHESIS, no. 12, 1986, pages 1027-1029, XP002081555
FRIEBE, Walter-Gunar
Sophienstrasse 8
D-68165 Mannheim
DE
SCHAUMANN, Wolfgang
Mönchhofstrasse 58
D-69120 Heidelberg
DE
WILHELMS, Otto-Henning
Odenwaldstrasse 25/2
D-69369 Weinheim
DE
Roche Diagnostics GmbH
00205395
Case 20205
Sandhofer Strasse 116
68305 Mannheim
DE
Witte, Hubert, Dr.
et al
00078221
F.Hoffmann-La Roche AG Patent Department (PLP), 124 Grenzacherstrasse
4070 Basel
CH
DE
ES
FR
GB
IT
EP1999000886
19990211
en
WO1999042089
19990826
199934
19991014
000000
The present invention relates to the use of thiadiazolo[4,3-a]pyridine derivatives for the production of medicaments for the treatment of proliferative disorders, including tumours, lymphomas, leukaemias, atherosclerosis and glomerulopathies memory and/or learning ability disorders, inter alia Alzheimer's, impotence, erectile insufficiency and obesity, ischaemic or thrombolytic disorders, such as coronary infarct or cerebral infarct and additionally serum disorders. The invention relates in particular to the use of substances having a great therapeutic breadth with preferred inhibition of phosphodiesterases of types III and IV, preferably of type IV.
Previously disclosed PDE IV inhibitors caused unpleasant side effects in experimental animals and in man, such as production of, for example, nausea, giddiness and vomiting, as well as undesired cardiovascular effects such as lowering of blood pressure and tachycardia. However, compounds of the general formula I showed a great therapeutic breadth in in-vivo animal models. The side effects of previously known PDE IV inhibitors can thus be markedly decreased.
The compounds according to the invention are thiadiazolo[4,3-a]pyridine derivatives of the general formula I in which
X^1 and X^2,
identically or differently, are hydrogen, a C_1- to C_6-alkyl radical or a halogen atom or, if they are in adjacent positions, form a fused phenyl ring together with the carbon atoms carrying them, and
R
is a carbocyclic or heterocyclic saturated or unsaturated radical, which if desired can be mono- or polysubstituted by halogen, cyano, nitro, C_1- to C_6-alkyl, C_1- to C_6-haloalkyl, hydroxyl, C_1- to C_6-alkoxy, methylenedioxy, C_1- to C_6-alkylthio, C_1- to C_6-haloalkylthio, amino, C_1- to C_6-alkylamino, C_2- to C_{12}-dialkylamino, pyrrolyl, carboxyl, carbamoyl, benzyl C_1- to C_6-hydroxyalkyl, C_2- to C_7-carboxyalkyl, C_2- to C_7-alkoxycarbonyl-C_1- to C_6-alkyl, carbamoyl-C_1- to C_6-alkyl, N-hydroxy-N-C_1- to C_6-alkylcarbamoyl-C_1- to C_6-alkyl or C_2- to C_6-alkenyl, and their physiologically tolerable salts.
The alkyl radicals in the mentioned alkyl, alkoxy, alkylthio and (di)alkylamino groups and also the alkenyl radicals can be straight-chain or branched. Preferred alkyl radicals in these groups are the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl and 3-pentyl radical, preferred alkenyl radicals are the vinyl and the allyl radical.
A C_1-C_6-haloalkyl radical is preferably trifluoromethyl.
Possible halogen atoms are fluorine, chlorine and bromine.
Carbocyclic radicals are the phenyl, cyclohexyl and cyclopentyl radical. Possible heterocyclic radicals are pyridyl, piperidinyl, pyrimidinyl, pyrrolidinyl, isoxazolyl, oxazolyl, thiazolyl, thiazolinyl, triazolyl and terrazolyl radicals.
Preferred compounds of the formula I are compounds in which X^1 is hydrogen, methyl or chlorine, X^2 is hydrogen or X^1 and X^2 together form a fused phenyl ring and R is a phenyl ring which can be mono- or disubstituted by fluorine, chlorine, methyl, mechoxy, tert-butyl, isopropoxy, trifluoromethyl, trifluoromethylthio, hydroxyl, nitrile, nitro, hydroxymethyl, methylenedioxy, diethylamino, methylthio, pyrrolyl, methoxycarbonylmethyl, carboxymethyl, N-hydroxy-N-methylcarbamoylmethyl or N-tetrazolylcarbamoylmethyl, or is a thiazolyl, pyridinyl, tetrazolyl, pyrimidyl or cyclohexyl radical.
Apart from the compounds mentioned in the examples, the invention relates in particular to all substances which have any possible combination of the substituents mentioned in the examples.
The synthesis of some of the compounds is described in WO 93/06109. Alternatively, a compound of the general formula II in which X^1 and X^2 have the abovementioned meaning, can be reacted in a known manner either
- a) with a compound of the formula III
ClSCCl_3 (III),
or a reactive derivative thereof
and a compound of the general formula IV
H_2N-R (IV),
in which R has the abovementioned meaning, or
- b) with a compound of the general formula V
YS-CY=N-R (V),
in which R has the abovementioned meaning and Y is a halogen atom,
and then, if desired, a radical R can be converted into another radical given by the definition and the compound of the formula I obtained, if desired, can be converted into a salt by reaction with physiologically tolerable acids or bases.
Possible halogen atoms for Y are, in particular, chlorine and bromine.
The process is preferably carried out in such a way that a compound of the general formula II is first condensed with a compound of the formula III and the product obtained is isolated. This intermediate is then reacted with a compound of the general formula IV.
Another variant consists in allowing the reaction mixture obtained from the reaction of a compound of the formula II with a compound of the formula III to react with a compound of the formula IV without isolation of the intermediate.
The reactions are expediently carried out in a solvent such as water, ether, a lower alcohol such as, for example, methanol or ethanol or a halogenated hydrocarbon such as dichloromethane or trichloromethane with addition of a base such as triethylamine or sodium carbonate at temperatures between -20 and 50°C, preferably between 0°C and room temperature.
The compounds of the formulae II, IV and V are known from the literature or can easily be prepared by trivial methods starting from known compounds.
Conversion of a radical R into another radical R is carried out, for example, by ether cleavage using a protic acid or Lewis acid such as hydrogen bromide, hydrogen chloride, hydrogen iodide, aluminium trichloride, boron trichloride or by alkylation of a hydroxyl group using the desired alkyl halide or alkyl sulphate.
A carboxyl group contained in R can be converted into an ester group or carboxamide function, if desired by means of a reactive derivative such as a halide, imidazolide or anhydride; an ester group contained in R can be converted into the carboxyl group by acidic or basic hydrolysis and into the carboxamide group by aminolysis.
Possible pharmacologically tolerable salts are, in particular, alkali metal, alkaline earth metal and ammonium salts and optionally salts with non-toxic inorganic or organic acids such as, for example, hydrochloric acid, sulphuric acid, phosphoric acid, hydrobromic acid, acetic acid, lactic acid, citric acid, malic acid, benzoic acid, salicylic acid, malonic acid, maleic acid, succinic acid or diaminocaproic acid.
The salts are obtained in a customary manner, e.g. by neutralization of the compounds of the formula I using the appropriate alkali solutions or acids.
It is described in WO 93/06109 that the compounds of the formula I inhibit the antigen-mediated contraction of lung tissue strips and prevent the lethality of an endotoxin shock.
PDE inhibitors intervene in the signal transduction cascade mediated by cyclic adenosine monophosphate (cAMP). PDE IV isoenzymes are found in various tissues and leukocyte types. They prevent the activation of leukocytes, thus also, inter alia, the secretion of TNF-α and can therefore also be used, for example, for treatment of cachexia.
The compounds of the formula I inhibit phosphodiesterase(s) (PDEs), preferably isoenzymes of the subclass type IV, with a simultaneous great therapeutic breadth. The compounds of the formula I are particularly suitable for medicaments for the preventive and/or symptomatic therapy of disorders whose causes lie in faulty regulation of intracellular signal transduction reactions which are controlled by cyclic nucleotides, in particular adenosine monophosphate (cAMP).
In particular, the compounds of formula I can be used for the production of medicaments for the treatment of disorders which are modulated by the inhibition of phosphodiesterase(s) (PDE) via cyclic nucleotides, especially cyclic adenosine monophosphate.
Disorders which can be preventively or therapeutically treated by the compounds of the general formula I are:
proliferatory disorders including tumours, lymphomas, leukaemias, atherosclerosis and glomerulopathies, furthermore disorders with reduction of learning ability and/or memory such as, for example, Alzheimer's syndrome, furthermore obesity, and also impotence and erectile insufficiency.
Surprisingly, it was possible to show that the compounds of the general formula I inhibit phosphodiesterase(s) (PDE), but preferably PDE of the subclass IV. Various isoenzymes of the phosphodiesterases are known (PDE I - PDE VII). PDE I, IV and V are found in mast cells, PDE III and IV in basophils, PDE IV in eosinophils, neutrophils and monocytes in each case, PDE II, III and IV in macrophages, PDE II-V and VII in T lymphocytes, PDE II, III and V in platelets, PDE II, IV and V in endothelial cells and PDE I-V in epithelial cells.
Compounds are preferred in which the quotient of the IC_{50} values of isolated PDE IV to PDE III is at least 2, particularly preferably greater than 3. Preferentially, the IC_{50} value for PDE IV is in the micromolar range, particularly preferably between 5 and 50 micromol.
The compounds of the general formula I exhibit a great therapeutic breadth in in-vivo animal models.
This is understood as meaning substances which have no disadvantageous side effects at a multiple of the therapeutically active plasma level in in-vivo tests. In the case of PDE III or IV inhibitors, side effects is understood as meaning a) lowering of the arterial blood pressure by more than 20%, b) raising of the heart rate by 20%, c) action on the CNS with production of stimulation, tremor, nausea and vomiting at oral doses which correspond to less than 2 times, preferably 5 times, the therapeutically necessary dose.
An example of a non-specific phosphodiesterase inhibitor employed for therapy and having a small therapeutic breadth is, for example, theophylline. Even at slightly increased doses, theophylline causes, inter alia, nausea, giddiness, tachycardia and tremor.
The compounds of the general formula I are suitable for the production of medicaments for the treatment of disorders which are modulated by inhibition of phosphodiesterases. Phosphodiesterase IV is preferably inhibited. Disorders which can be preventively or therapeutically treated by the compounds of the general formula I are: proliferative disorders including tumours, lymphomas, leukaemias, atherosclerosis and glomerulopathies, memory and/or learning ability disorders (inter alia Alzheimer's), impotency due to erectile insufficiency and obesity, furthermore, for example, ischaemic or thrombolytic disorders, such as, for example, coronary infarct or cerebral infarct and additionally serum sickness.
For the production of medicaments, the compounds of the general formula I are mixed in a manner known per se with suitable pharmaceutical excipients, aromatizers, flavourings and colourants and shaped, for example, as tablets or coated tablets or suspended or dissolved in water or oil, such as, for example, olive oil, with addition of appropriate auxiliaries.
The substances of the general formula I can be administered orally and parenterally in liquid or solid form. The injection medium used is preferably water which contains the stabilizers, solubilizers and/or buffers customary in the case of injection solutions. Additives of this type are, for example, tartrate or borate buffers, ethanol, dimethyl sulphoxide, complexing agents (such as ethylenediaminetetraacetic acid), high molecular weight polymers (such as liquid polyethylene oxide) for viscosity regulation or polyethylene derivatives of sorbitol anhydrides.
Solid excipients are, for example, starch, lactose, mannitol, methylcellulose, talc, highly disperse silicic acid, higher molecular weight polymers (such as polyethylene glycols).
If desired, preparations suitable for oral administration can contain flavourings and sweeteners. For external application, the substances I according to the invention can also be used in the form of powders, ointments and patches. To this end, they are mixed, for example, with powdered, physiologically tolerable diluents or customary ointment bases or attached to a patch base using customary technology.
The dose administered depends on the age, the health and the weight of the recipient, the extent of disease, the nature of simultaneous further treatments which are optionally carried out, the frequency of the treatment and the type of action desired. Customarily, the daily dose of the active compound is 0.1 to 50 mg/kg of body weight. Normally, 0.5 to 40 and preferably 1.0 to 20 mg/kg/day in one or more administrations per day are effective in order to obtain the desired results.
This dose can be given in the form of 1, 2 or more tablets daily. Alternatively, with suitable pharmaceutical technology, administration can be carried out every 2 days. The person skilled in the art can easily determine from the daily dose the appropriate active compound content of the tablets, depending on the administration scheme.
Apart from the substances mentioned in the examples, within the meaning of the present invention the use of the following compounds is preferred:
- 1. 4-(3H-[1,2,4]Thiadiazolo[4,3-a]pyridin-3-ylidene-amino)phenylacetic acid N-(1H-tetrazol-5-yl)amide
- 2. 3-(2-Pyrimidinylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine
- 3. 5-Methyl-3-(4-pyridinylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine
- 4. 6-Methyl-3-(4-pyridinylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine
- 5. 8-Methyl-3-(4-pyridinylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine

Example 1

3-(Thiazol-2-ylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine
A solution of 5.6 g (60 mmol) of 2-aminopyridine and 8.3 ml of triethylamine in 50 ml of chloroform is added dropwise at 0°C to a solution of 6.6 ml (60 mmol) of trichloromethanesulphenyl chloride in 900 ml of chloroform. The mixture is stirred for 10 min and a solution of 6.0 g (60 mmol) of 2-aminothiazole and 25 ml of triethylamine in 100 ml of chloroform is added dropwise. After stirring at room temperature for 3 h, the mixture is concentrated and the precipitate is washed with methanol. 8.9 g of title compound (63% of theory) of m.p. 169-171°C remain.

Example 2
The following are obtained from trichloromethanesulphenyl chloride, 2-aminopyridine and the respective amine in a manner analogous to that described in Example 1:
Designation | Yield % | Melting point °C (solvent)
a) | 3-(2-Pyridinylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from 2-aminopyridine | 80 | 159-161 (ether)
b) | 3-(4-Pyridinylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from 4-aminopyridine | 37 | 185-186 (ethanol)
c) | 3-Phenylimino-3H-[1,2,4]-thiadiazol[4,3-a]pyridine from aniline | 67 | 64-86 (propanol)
d) | 3-(4-Chlorophenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from 4-chloroaniline | 64 | 129-130 (2-propanol)
e) | 3-(4-Methoxyphenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from 4-methoxyaniline | 69 | 90-92 (2-propanol)
f) | 3-(4-Cyanophenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from 4-aminobenzonitrile | 57 | 149-150 (2-propanol)
g) | 3-(4-Nitrophenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine from 4-nitroaniline | 63 | 198-199 (2-propanol)
h) | 3-Cyclohexylimino-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine hydrochloride from cyclohexylamine | 28 | 194-196 (ethyl acetate)
i) | 3-(5-1H-Tetrazolylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from 5-amino-1H-tetrazole | 29 | 282-283 (water)
j) | 3-(4-Fluorophenylamino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from 4-fluoroaniline | 67 | 138-140 (2-propanol)
k) | 3-(2,4-Dichlorophenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from 2,4-dichloroaniline | 51 | 130-132 (2-propanol)
l) | 3-(4-Methylphenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from 4-methylaniline | 59 | 106-108 (2-propanol)
m) | 3-(3-Trifluoromethylphenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]-pyridine from 3-trifluoromethylaniline | 34 | 48-49 (2-propanol)
n) | 3-(2-Hydroxymethylphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine from 2-aminobenzyl alcohol | 49 | 118-119 (2-propanol)
o) | 3-(2-Hydroxyphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine from 2-aminophenol | 21 | 130-132 (2-propanol)
p) | 3-(4-Hydroxy-2-methylphenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]-pyridine from 4-amino-3-methylphenol | 49 | 241-243 (2-propanol)
q) | 3-(3,4-Methylenedioxyphenylimino-3H-[1,2,4]thiadiazolo-[4,3-a]-pyridine from 3,4-methylenedioxyaniline | 49 | 141-143 (2-propanol)
r) | 3-(3-Trifluoromethylthiophenylimino)-3H-[1,2,4]thiadiazolo-[4,3-a]pyridine from 3-trifluoromethylthioaniline | 70 | 86-88 (2-propanol)
s) | 3-(4-Diethylaminophenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from N,N-diethyl-1,4-phenylenediamine | 54 | 96-97 (2-propanol)
t) | 3-(5-Methylisoxazol-3-ylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from 3-amino-5-methylisoxazole | 36 | 170-172 (2-propanol)
u) | 3-(4,5-Dihydrothiazol-2-ylimino)-3H-[1,2,4]thiadiazolo[4,3-a]-pyridine from 2-amino-2-thiazoline | 55 | 106-108 (2-propanol)
v) | 3-(1-Benzylpiperidin-4-ylimino)-3H-[1,2,4]thiadiazolo[4,3-a]-pyridine from 4-amino-1-benzylpiperidine | 55 | 90-92 (2-propanol)
w) | 3-(3-Pyridinylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine from 3-aminopyridine | 67 | 133-134 (2-propanol)
x) | 3-(4-t-Butylphenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from 4-t-butylaniline | 46 | 72-74 (isohexane)
y) | 3-(4-Isopropoxyphenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from 4-isopropoxyaniline | 52 | 94-95 (ether)
z) | 3-(4-Methylthiophenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from 4-methylmercaptoaniline | 76 | 111-112 (2-propanol)
aa) | 3-(4-Pyrrolophenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine from N-(4-aminophenyl)pyrrole | 68 | 167-168 (ethyl acetate)

Example 3

7-Methyl-3-(4-pyridinylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine
A solution of 3.2 g (30 mmol) of 2-amino-4-methylpyridine and 4.2 ml of triethylamine in 25 ml of dichloromethane is added dropwise at 0°C to a solution of 3.3 ml (30 mmol) of trichloromethanesulphenyl chloride in 450 ml of dichloromethane, the mixture is stirred for 10 min and a solution of 2.8 g (30 mmol) of 4-aminopyridine and 12 ml of triethylamine in 100 ml of dichloromethane is added dropwise. After stirring at room temperature for 3 h, the mixture is poured into water and extracted with ethyl acetate, the extract is dried and concentrated, and the residue is chromatographed on silica gel (eluant ethyl acetate/ isohexane 1:1). 1.2 g of title compound (17% of theory) of m.p. 144-145°C are isolated.

Example 4

6-Chloro-3-(4-pyridinylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine
In an analogous manner to that described in Example 3, the title compound of m.p. 205-207°C is obtained in 20% yield from 2-amino-5-chloropyridine and 4-aminopyridine.

Example 5

3-Phenylimino-3H-[1,2,4]-thiadiazolo[4,3-a]quinoline
A solution of 4.1 g (21 mmol) of 1-chloro-1-phenyliminomethanesulphenyl chloride in 20 ml of dichloromethane is added dropwise at 0°C to a solution of 3.1 g (21 mmol) of 2-aminoquinoline and 6 ml of triethylamine in 70 ml of dichloromethane, the mixture is stirred for 3 h at room temperature, the organic phase is washed with water, dried and concentrated, and the residue is chromatographed on silica gel. Using isohexane/ethyl acetate 9:1, 2.3 g of title compound (39% of theory) of m.p. 116-118°C are eluted.

Example 6

3-(4-Pyridinylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]quinoline
In an analogous manner to that described in Example 3, the title compound of m.p. 180-182°C is obtained in 11% yield from 2-aminoquinoline and 4-aminopyridine.

Example 7

3-(4-Methoxycarbonylmethylphenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine
In an analogous manner to that described in Example 1, the title compound of m.p. 151-152°C (from ethyl acetate) is obtained in 41% yield from 2-aminopyridine and methyl 4-aminophenylacetate.

Example 8

4-(3H-[1,2,4]Thiadiazolo[4,3-a]pyridin-3-ylidenamino)phenylacetic acid hydrochloride
A mixture of 9.0 g (30 mmol) of the compound of Example 7, 100 ml of ethanol and 300 ml of N hydrochloric acid is stirred at 50°C for 6 h. The mixture is concentrated and the residue is triturated with acetone. 8.9 g of title compound (92% of theory) of m.p. 209-211°C remain.

Example 9

4-(3H-[1,2,4]Thiadiazolo[4,3-a]-pyridin-3-ylidenamino)phenylacetic acid N-methylhydroxamide
A solution of 1.7 ml of oxalyl chloride in 15 ml of dichloromethane is added dropwise at 0°C to a mixture of 4.8 g (15 mmol) of the compound of Example 8, 90 ml of dichloromethane and 1 ml of dimethylformamide. The solution obtained is stirred for 40 min and then added dropwise to a solution of 5.0 g of N-methylhydroxylamine in 15 ml of triethylamine, 10 ml of water and 60 ml of tetrahydrofuran. After stirring for 30 mm, the mixture is treated with 20 ml of water and extracted with dichloromethane, the extract is dried and concentrated, and the residue is purified on silica gel (eluent trichloroethane/methanol 95:5). 3.4 g of title compound (78% of theory) are isolated, which after trituration with ether melt at 135-136°C.

Pharmacological investigations

Example 10
The IC_{50} values of the compound from Example 2b were determined to be 2 × 10^{-5} mol/l (PDE IV) and 8 × 10^{-5} mol/l (PDE III) on isolated human enzyme preparations.

Example 11

Anti-proliferatory action in vitro
The compound from Example 2b inhibits the activation of various types of leucocytes under different stimuli. Cell types, parameters in order to determine the activation and IC_{50} values (mg/l) are summarized in Table 1

Table 1
Cell type | Stimulus | Parameter:Inhibition v. | IC_{50}
Peripheral leucocytes | LPS | Secretion of TNFα | <3
Lymphocytes | ConA | Thymidine incorporation | 2.8
Lymphocytes | Mixed lymphocytes reaction | Thymidine incorporation | 7.6
T Lymphoblasts | - | Thymidine incorporation | 6.4
Basophilic granulocytes | Anti-IgE antibody | Proteinase release | 10
Phagocytes (PMNs) | Zymosan | Chemiluminescence | 27

Example 12

Toxicity and therapeutic breadth
The compound from Example 2b is well tolerated by small experimental animals (mice, rats, guinea pigs p.o. and i.p.) and by dogs p.o. It was not possible to determine any side effects (behaviour, body weight, histology, haematological and clinicochemical parameters) in rats after 2 weeks (40 mg/kg daily). In conscious dogs (beagles), the heart rate and the arterial blood pressure on administration of 24 mg/kg of the compound from Example 2b remained constant in the observation period up to 6 h after administration (see Table 2). The behaviour of the dogs was normal. The emetic action typical of PDE IV inhibitors as a sign of CNS effects was not detectable.
It was moreover found that triglycerides and GPT (the latter as a sign of liver damage) and blood glucose remained unchanged in the observation period.
Doses of this type caused average plasma levels of the active substances over several hours after administration which (markedly) exceed the necessary in vitro concentrations for significant inhibition of isolated humane PDE N or for inhibition of secretion of, for example TNF alpha (in each case 2 × 10^{-5} mol/l).
1. Use of compounds of the formula I in which
X^1 and X^2, identically or differently, are hydrogen, a C_1- to C_6-alkyl radical or a halogen atom or, if they are in adjacent positions, form a fused phenyl ring together with the carbon atoms carrying them, and
R is a carbocyclic or heterocyclic saturated or unsaturated radical, which if desired can be mono- or polysubstituted by halogen, cyano, nitro, C_1- to C_6-alkyl, C_1- to C_6-haloalkyl, hydroxyl, C_1- to C_6-alkoxy, methylenedioxy, C_1- to C_6-alkylthio, C_1- to C_6-haloalkylthio, amino, C_1- to C_6-alkylamino, C_2- to C_{12}-dialkylamino, pyrrolyl, carboxyl, carbamoyl, benzyl, C_1- to C_6-hydroxyalkyl, C_2- to C_7-carboxyalkyl, C_2- to C_7-alkoxycarbonyl-C_1- to C_6-alkyl, carbamoyl-C_1- to C_6-alkyl, N-hydroxy-N-C_1- to C_6-alkylcarbamoyl-C_1- to C_6-alkyl or C_2- to C_6-alkenyl,
as well as their physiologically tolerable salts,
for the production of a medicament for the treatment of proliferative disorders, including tumours, lymphomas, leukaemias, atherosclerosis and glomerulopathies, memory and/or learning ability disorders, inter alia Alzheimer's, impotence, erectile insufficiency and obesity, ischaemic or thrombolytic disorders, such as coronary infarct or cerebral infarct and additionally serum disorders.
2. Use according to claim 1, wherein
X^1 is hydrogen, methyl or chlorine,
X^2 is hydrogen; or
X^1 and X^2 together form a fused phenyl ring, and
R is a phenyl ring which can be mono- or disubstituted by fluorine, chlorine, methyl, methoxy, tert.butyl, isopropoxy, trifluoromethyl, trifluoromethylthio, hydroxyl, nitrile, nitro, hydroxymethyl, methylenedioxy, diethylamino, methylthio, pyrrolyl,methoxycarbonylmethyl, carboxy- methyl,N-hydroxy-N-methyl-carbamoyl- methyl or N-tetrazolyl-carbamoylmethyl, or is a thiazolyl, pyridinyl, tetrazolyl, pyrimidyl or cyclohexyl radical.
3. Use according to claim 1, wherein the compound is selected from
3-(thiazol-2-yl-imino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-(2-pyridinyl-imino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-(4-pyridinyl-imino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-phenylimino-3H-[1,2,4]-thiadiazol[4,3-a]pyridine,
3-(4-chloro-phenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-[4-methoxy-phenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-(4-cyano-phenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-(4-nitro-phenylimino)-3H-[1,2,4]- thiadiazolo[4,3-a]pyridine,
3-cyclohexylimino-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine-hydrochloroid,
3-(5-lH-tetrazolyl-imino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-(4-fluoro-phenylamino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-(2,4-dichloro-phenylimino)-3H-[1,2,4]-thiadiazolo[4, 3-a]pyridine,
3-(4-methyl-phenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-(3-trifluoromethyl-phenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(2-hydroxymethyl-phenylimino)-3H-[1,2,4]-thia-diazolo[4,3-a]pyridine,
3-(2-hydroxy-phenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-(4-hydroxy-2-methyl-phenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(3,4-methylenedioxy-phenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(3-trifluoromethylthio-phenylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(4-diethylamino-phenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-(5-methyl-isoxazol-3-ylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-(4,5-dihydro-thiazole-2-ylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(1-benzyl-piperidin-4-ylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-(3-pyridinyl-imino)-3H-[1, 2,4]-thiadiazolo[4,3-a]pyridine,
3-(4-t-butyl-phenylimino)-3H-[1,2,4]-thiadiazolo[4, 3-a]pyridine,
3-(4-isopropoxy-phenylimino)-3H-[1,2,4]-thiadiazolo[4, 3-a]pyridine,
3-(4-methylthio-phenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
3-(4-pyrrolo-phenylimino)-3H-[1,2,4]-thiadiazolo-[4,3-a]pyridine,
7-methyl-3-(4-pyridinyl-imino)-3H-[1,2,4]-thiadia-zolo[4,3-a]pyridine,
6-chloro-3-(4-pyridinyl-imino)-3H-[1,2,4]-thiadia-zolo[4,3-a]pyridine,
3-phenylimino-3H-[1,2,4]-thiadiazolo[4,3-a]quinoline,
3-(4-pyridinyl-imino)-3H-[1,2,4]-thiadiazolo[4,3-a]quinoline,
3-(4-methoxycarbonylmethyl-phenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridine,
4-(3H-[1,2,4]-thiadiazolo[4,3-a]pyridin-3-ylideneamino)-phenylacetic acid hydrochloride and
4-(3H-[1,2,4]-thiadiazolo[4,3-a]pyridine-3-ylideneamino)-phenylacetic acid N-methyl-hydroxamide.
1. Verwendung von Verbindungen der Formel I in welcher
X^1 und X^2 gleich oder verschieden ein Wasserstoffatom, einen C_{1-6}-Alkylrest oder ein Halogenatom bedeuten oder, sofern sie in benachbarten Positionen stehen, zusammen mit den sie tragenden Kohlenstoffatomen einen ankondensierten Phenylring bilden, und
R einen carbocyclischen oder heterocyclischen gesättigten oder ungesättigten Rest, welcher gewünschtenfalls ein- oder mehrfach mit einem Halogenatom, einer Cyano-, Nitrogruppe, einem C_{1-6}-Alkyl-, C_{1-6}-Halogenalkylrest, einer Hydroxygruppe, einem C_{1-6}-Alkoxy-, Methylendioxy-, C_{1-6}-Alkylthio-, C_{1-6}-Halogenalkylthio-, Amino-, C_{1-6}-Alkylamino-, C_{2-12}-Dialkylaminorest, einer Pyrrolyl-, Carboxyl-, Carbamoyl-, Benzylgruppe, einem C_{1-6}-Hydroxyalkyl-, C_{2-7}-Carboxyalkyl-, C_{2-7}-Alkoxcarbonyl-C_{1-6}-alkyl-, Carbamoyl-C_{1-6}-alkyl-, N-Hydroxy-N-C_{1-6}-alkylcarbamoyl-C_{1-6}-Alkyl- oder C_{2-6}-Alkenylrest substituiert sein kann, bedeutet,
sowie deren physiologisch verträglichen Salze,
zur Herstellung eines Arzneimittels zur Behandlung von proliferativen Erkrankungen einschließlich Tumoren, Lymphomen, Leukämien, Atherosklerose und Glomerulopathien, Gedächtnis- und/oder Lemfähigkeitsstörungen, u.a. Alzheimer-Krankheit, Impotenz, Erektionsschwäche und Obesität, ischämische oder thrombolytische Erkrankungen, wie Coronarinfarkt oder Cerebralinfarkt und außerdem Serumerkrankungen.
2. Verwendung gemäß Anspruch 1, wobei
X^1 ein Wasserstoffatom, eine Methylgruppe oder ein Chloratom bedeutet,
X^2 ein Wasserstoffatom bedeutet; oder
X^1 und X^2 zusammen einen ankondensierten Phenylring bilden, und
R einen Phenylring, welcher ein- oder zweifach mit einem Fluor-, Chloratom, einer Methyl-, Methoxy-, tert.-Butyl-, Isopropoxy-, Trifluormethyl-, Trifluormethylthio-, Hydroxy-, Nitril-, Nitro-, Hydroxymethyl-, Methylendioxy-, Diethylamino-, Methylthio-, Pyrrolyl-, Methoxycarbonylmethyl-, Carboxymethyl-, N-Hydroxy-N-methylcarbamoylmethyl- oder N-Tetrazolylcarbamoylmethylgruppe substituiert sein kann, oder einen Thiazolyl-, Pyridinyl-, Tetrazolyl-, Pyrimidyl- oder Cyclohexylrest darstellt.
3. Verwendung einer Verbindung gemäß Anspruch 1, welche ausgewählt ist aus
3-(Thiazol-2-ylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(2-Pyridinylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(4-Pyridinylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-Phenylimino-3H-[1,2,4]-thiadiazol[4,3-a]pyridin,
3-(4-Chlorphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(4-Methoxyphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(4-Cyanophenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(4-Nitrophenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-Cyclohexylimino-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin-hydrochlorid,
3-(5-1H-Tetrazolylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(4-Fluorphenylamino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(2,4-Dichlorphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(4-Methylphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(3-Trifluormethylphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(2-Hydroxymethylphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(2-Hydroxyphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(4-Hydroxy-2-methylphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(3,4-Methylendioxyphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(3-Trifluormethylthiophenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(4-Diethylaminophenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(5-Methylisoxazol-3-ylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(4,5-Dihydrothiazol-2-ylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(1-Benzylpiperidin-4-ylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(3-Pyridinylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(4-t-Butylphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(4-Isopropoxyphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(4-Methylthiophenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-(4-Pyrrolophenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
7-Methyl-3-(4-pyridinylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
6-Chlor-3-(4-pyridinylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
3-Phenylimino-3H-[1,2,4]-thiadiazolo[4,3-a]chinolin,
3-(4-Pyridinylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]chinolin,
3-(4-Methoxycarbonylmethylphenylimino)-3H-[1,2,4]-thiadiazolo[4,3-a]pyridin,
4-(3H-[1,2,4]-Thiadiazolo[4,3-a]pyridin-3-ylidenamino)-phenylessigsäure-hydrochlorid und
4-(3H-[1,2,4]-Thiadiazolo[4,3-a]pyridin-3-ylidenamino]-phenylessigsäure-N-methylhydroxamid.
1. Utilisation de composés de formule I dans laquelle
X^1 et X^2 sont identiques ou différents et représentent chacun un atome d'hydrogène, un radical alkyle en C_1 à C_6 ou un atome d'halogène ou encore, s'ils se trouvent sur des positions adjacentes, forment un noyau phényle condensé avec les atomes de carbones qui les portent, et
R est un radical carbocyclique ou hétérocyclique saturé ou insaturé, qui, si on le souhaite, peut être une ou plusieurs fois substitué par des substituants halogéno, cyano, nitro, alkyle en C_1 à C_6, halogènoalkyle en C_1 à C_6, hydroxyle, alcoxy en C_1 à C_6, méthylènedioxy, alkylthio en C_1 à C_6, halogènoalkylthio en C_1 à C_6, amino, alkylamino en C_1 à C_6, dialkylamino en C_2 à C_{12}, pyrrolyle, carboxyle, carbamoyle, benzyle, hydroxyalkyle en C_1 à C_6, carboxyalkyle en C_2 à C_7, (alcoxycarbonyle en C_2 à C_7)(alkyle en C_1 à C_6), carbamoyl(alkyle en C_1 à C_6), N-hydroxy-N-(alkyle en C_1 à C_6)carbamoyl(alkyle en C_1 à C_6) ou alcényle en C_2 à C_6,
ainsi que de leurs sels tolérés d'un point de vue physiologique,
pour la production d'un médicament destiné au traitement des troubles prolifératifs, parmi lesquels les tumeurs, les lymphomes, les leucémies, l'athérosclérose et les glomérulopathies, les troubles de la mémoire et/ou de l'aptitude à l'apprentissage, entre autres la maladie d'Alzheimer, l'impuissance, l'insuffisance d'érection et l'obésité, les troubles ischémiques ou thrombolytiques tels que l'infarctus coronarien ou l'infarctus cérébral, et en outre les troubles du sérum.
2. Utilisation selon la revendication 1, dans laquelle
X^1 est un atome d'hydrogène ou le groupe méthyle ou chloro,
X^2 est un atome d'hydrogène ; ou bien
X^1 et X^2 forment ensemble un noyau phényle condensé ; et
R est un noyau phényle qui peut être une ou deux fois substitué par des substituants fluoro, chloro, méthyle, méthoxy, tert-butyle, isopropoxy, tri-fluorométhyle, trifluorométhylthio, hydroxyle, nitrile, nitro, hydroxyméthyle, méthylènedioxy, diéthylamino, méthylthio, pyrrolyle, méthoxycarbonylméthyle, carboxy-méthyle, N-hydroxy-N-méthylcarbamoylméthyle ou N-tétrazolylcarbamoylméthyle, ou encore est un radical thiazolyle, pyridinyle, tétrazolyle, pyrimidyle ou cyclohexyle.
3. Utilisation selon la revendication 1, dans laquelle le composé est choisi parmi les composés suivants :
3-(thiazole-2-yl-imino)-3H-[1,2,4]thiadiazolo[4,3-a] pyridine,
3-(2-pyridinyl-imino)-3H-[1,2,4]thiadiazolo[4,3-a] pyridine,
3-(4-pyridinyl-imino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-phénylimino-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(4-chloro-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a] pyridine,
3-(4-méthoxy-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(4-cyano-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(4-nitro-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a] pyridine,
Chlorhydrate de 3-cyclohexylimino-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(5-1H-tétrazolyl-imino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(4-fluoro-phénylamino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3- (2,4-dichloro-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(4-méthyl-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(3-trifluorométhyl-phénylimino)-3H-[1,2,4]thiadiazolo [4,3-a]pyridine,
3-(2-hydroxyméthyl-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3- (2-hydroxy-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3- (4-hydroxy-2-méthyl-phénylimino)-3H- [1,2,4]thiadiazolo[4,3-a]pyridine,
3- (3,4-méthylènedioxy-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(3-trifluorométhylthio-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(4-diéthylamino-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(5-méthyl-isoxazole-3-ylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(4,5-dihydro-thiazole-2-ylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(1-benzyl-pipéridine-4-ylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(3-pyridinyl-imino)-3H-[1,2,4]thiadiazolo[4,3a]pyridine,
3-(4-tert-butyl-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(4-isopropoxy-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(4-méthylthio-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-(4-pyrrolo-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
7-méthyl-3-(4-pyridinyl-imino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
6-chloro-3-(4-pyridinyl-imino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
3-phénylimino-3H-[1,2,4]thiadiazolo[4,3-a]quinoléine,
3-(4-pyridinyl-imino)-3H-[1,2,4]thiadiazolo[4,3-a] quinoléine,
3-(4-méthoxycarbonylméthyl-phénylimino)-3H-[1,2,4]thiadiazolo[4,3-a]pyridine,
Chlorhydrate de l'acide 4-(3H-[1,2,4]thiadiazolo[4,3-a]pyridine-3-ylidène-amino)phénylacétique, et
N-méthyl-hydroxamide de l'acide 4-(3H-[1,2,4]thiadiazolo[4,3-a]pyridine-3-ylidèneamino)-phénylacétique.